MNKD - マンカインド (MannKind Corporation) マンカインド

 MNKDのチャート


 MNKDの企業情報

symbol MNKD
会社名 MannKind Corp (マンカインド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マンカインド(MannKind Corporation)は開発段階の生物薬剤学企業であり、糖尿病と癌など疾患用の治療薬の発見・開発・商業化に集中する。同社の製品候補AFREZZA(ヒトインスリン)吸入パウダーは、血糖コントロールのための1型や2型糖尿病を患う成人向けの治療用の後期臨床研究段階にあるインスリン。AFREZZA吸入パウダーは、酸性・塩基性度(pH) 感知の有機分子クラスに集中する。AFREZZAはテクノスフィア処方設計技術を利用する。平成23年12月31日現在、同社の製品より収入はない。平成23年12月31日現在、AFREZZA臨床プログラムは、61の異なるAFREZZA研究及び5600以上の成人患者を含まれている。   マンカインドは米国のバイオ医薬品メ―カ―。主に糖尿病疾患の治療薬の発見・開発・製品化に従事。製品候補のAFREZZA(ヒトインスリン)吸入粉末は、I型またはII型糖尿病成人における血糖コントロ―ルを改善する可能性がある。AFREZZAはテクノスフィア製剤技術を利用している。本社はカリフォルニア州。   MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.
本社所在地 25134 Rye Canyon Loop Suite 300 Valencia CA 91355 USA
代表者氏名 Kent Kresa ケント・クレッサ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 818-661-5000
設立年月日 33270
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 192人
url www.mannkindcorp.com
nasdaq_url https://www.nasdaq.com/symbol/mnkd
adr_tso
EBITDA EBITDA(百万ドル) -98.39600
終値(lastsale) 1.71
時価総額(marketcap) 271441752.57
時価総額 時価総額(百万ドル) 304.44680
売上高 売上高(百万ドル) 13.93100
企業価値(EV) 企業価値(EV)(百万ドル) 407.62780
当期純利益 当期純利益(百万ドル) -118.73000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MannKind Corporation revenues increased 42% to $7.4M. Net loss increased 3% to $53.1M. Revenues reflect Net revenue - commercial product sales increase from $2.7M to $7.2M Net revenue - collaboration increase of 19% to $150K. Higher net loss reflects General and Administrative increase of 25% to $42.3M (expense) Interest Exp-Net of Capitalized Interest increase of 51% to $2.2M (expense).

 MNKDのテクニカル分析


 MNKDのニュース

   Take a deep breath  2021/07/19 14:37:33 Diabetic Investor
Yes we know that Monday isnt the normal day to release another version of our Wacky World of Diabetes podcast but this isnt exactly a normal podcast either as we are delighted to welcome Michael Castagna CEO of MannKind to our list of distinguished guest. As longtime subscribers know weve been following MannKind since day [] The post Take a deep breath appeared first on Diabetic Investor .
   Have an attention on: MannKind Corporation (NASDAQ:MNKD), The Williams Companies, Inc. (NYSE:WMB)  2021/07/18 23:05:42 Stock Equity
MannKind Corporation (MNKD) with the stream of -0.90% also noticed, India The Williams Companies, Inc. (WMB) encountered a rapid change of -1.10% in the last hour of trading session. MannKind The post Have an attention on: MannKind Corporation (NASDAQ:MNKD), The Williams Companies, Inc. (NYSE:WMB) appeared first on Stocks Equity .
   Investors Alert (Technical Performance Analysis): Tempest Therapeutics Inc. (NASDAQ:TPST), MannKind Corporation (NASDAQ:MNKD)  2021/07/11 21:18:46 Stock Equity
Tempest Therapeutics Inc. (TPST) with the stream of 49.38% also noticed, India MannKind Corporation (MNKD) encountered a rapid change of -1.23% in the last hour of Fridays trading session. Tempest The post Investors Alert (Technical Performance Analysis): Tempest Therapeutics Inc. (NASDAQ:TPST), MannKind Corporation (NASDAQ:MNKD) appeared first on Stocks Equity .
   Pulmonary Drug Delivery Market In-Depth Analysis Of Competitive Landscape Executive Summary Development Factors 2028-F. Hoffmann-La Roche Ltd., MannKind Corporation, OMRON Corporation  2021/07/08 06:55:42 OpenPR
Pulmonary Drug Delivery Market research report gives insightful analysis of the market along with its comprehensive understanding and its commercial landscape. The report offers market share appraisals for regional and global levels. It gives detailed overview of the parent market.
   Is The Stock Worthy? Sunrun Inc. (NASDAQ:RUN), MannKind Corporation (NASDAQ:MNKD)  2021/07/07 22:25:39 Stock Equity
Sunrun Inc. (NASDAQ:RUN) with the stream of -4.17% also noticed, India MannKind Corporation (NASDAQ:MNKD) encountered a rapid change of -2.49% in the last hour of Wednesdays trading session. Sunrun Inc. The post Is The Stock Worthy? Sunrun Inc. (NASDAQ:RUN), MannKind Corporation (NASDAQ:MNKD) appeared first on Stocks Equity .
   Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027  2021/06/29 12:55:00 Benzinga
PALM BEACH, Fla., June 29, 2021 /PRNewswire/ -- Cancer is a foremost public health problem globally and is the second leading cause of death in the United States. According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021. This market entails drugs used to treat the human brain for the mass growth of abnormal cells. Depending on the size, type, and location of the tumor, such drugs are either used alone or in combinations. On the other hand, the burden of the rising prevalence of oncological diseases and the growing geriatric population globally is leading to a surge in the sales of products, as well as clinical trials in the global market. Moreover, initiatives taken by the government to enhance healthcare infrastructure, coupled with collaborative efforts by pharmaceutical companies, for spreading awareness about the availability of various therapies are expected to accelerate the market growth during the forecast period.
   Hot Stock in Focus: MannKind Corporation (NASDAQ:MNKD), Johnson & Johnson (NYSE:JNJ)  2021/06/28 22:46:37 Stock Equity
MannKind Corporation (MNKD) with the stream of 11.18% also noticed, India Johnson & Johnson (JNJ) encountered a rapid change of -0.14% in the last hour of Mondays trading session. MannKind The post Hot Stock in Focus: MannKind Corporation (NASDAQ:MNKD), Johnson & Johnson (NYSE:JNJ) appeared first on Stocks Equity .
   MannKind (MNKD) Stock Rokets On Afrezza Access - CNA Finance  2021/06/28 12:23:10 CNA Finance
MNKD stock is screaming for the top after news broke that Medicare patients will have expanded access to Afrezza.
   Cramer Gives His Opinion On Carlotz, MannKind And More  2021/06/28 11:50:45 Benzinga
On CNBC''s "Mad Money Lightning Round," Jim Cramer said he is staying away from Carlotz Inc (NASDAQ: LOTZ ). He is done with the Full story available on Benzinga.com
   MannKind welcomes recent CMS decision on inhaled insulin therapy  2021/06/28 11:15:07 Seeking Alpha
   MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference - Stocks News Feed  2021/03/02 22:00:00 Stocks News Feed
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the H.C. Wainwright Global Life Sciences Conference which will… Read More »MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
   MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference - Stocks News Feed  2021/02/18 22:00:00 Stocks News Feed
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2021 SVB Leerink Global Healthcare… Read More »MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
   The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street  2021/02/05 12:43:46 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 4) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agenus Inc (NASDAQ: AGEN ) (announced positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19) Anavex Life Sciences Corp (NASDAQ: AVXL ) AngioDynamics, Inc. (NASDAQ: ANGO ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) BioVie Inc (NASDAQ: BIVI ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) (announced new data on validity and accuracy of skin cancer diagnostics test in patients with T1 cutaneous melanoma tumors) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) ChemoCentryx Inc (NASDAQ: CCXI ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) CorMedix Inc. Common Stock (NASDAQ: CRMD ) DermTech Inc (NASDAQ: DMTK ) Evogene Ltd (NASDAQ: EVGN ) F-Star Therapeutics Inc (NASDAQ: FSTX ) Glaukos Corp (NYSE: GKOS ) Gracell Biotechnologies Inc (NASDAQ: GRCL ) Halozyme Therapeutics, Inc.
   Here Are The Companies WallStreetBets May Target Next  2021/02/04 18:30:00 Zero Hedge
Here Are The Companies WallStreetBets May Target Next With Gamestop stock in freefall, down more than 85% from its all time highs and dragging many of the other most shorted "meme" stocks that soared at the end of January… ... the question on every trader's mind is whether the squeeze (and hedge fund deleveraging) is finally over and is it safe to go back to shorting again? Addressing this point, JPM strategists published a report overnight in which they note that the most common questions people are asking are “does the de-risking persist?” or“what do we expect going forward? ” As JPM explains, it seems likely that we’re through most of the extreme deleveraging, especially among L/S funds, given how much L/S funds de-grossed last week and how negative alpha spreads were. Validating this point, the strategists point to the improving HF returns that are getting reported in the press so far which suggest that there were bright spots within L/S last month, while other strategies generally held up better than L/S.
   MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference  2021/01/04 22:00:00 GlobeNewswire
WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マンカインド MNKD MannKind Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)